Literature DB >> 12488356

Central administration of neuropeptide Y reduces alpha-melanocyte-stimulating hormone-induced cyclic adenosine 5'-monophosphate response element binding protein (CREB) phosphorylation in pro-thyrotropin-releasing hormone neurons and increases CREB phosphorylation in corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus.

Sumit Sarkar1, Ronald M Lechan.   

Abstract

Neuropeptide Y (NPY) has a potent inhibitory effect on TRH gene expression in the paraventricular nucleus (PVN) and contributes to the fall in circulating thyroid hormone levels during fasting mediated by a reduction in serum leptin levels. Because alpha-MSH activates the TRH gene by increasing the phosphorylation of CREB in the nucleus of these neurons, we raised the possibility that at least one of the mechanisms by which NPY reduces TRH mRNA in hypophysiotropic neurons is by antagonizing the ability of alpha-MSH to phosphorylate CREB. As NPY increases CRH mRNA in the hypothalamus, we further determined whether intracerebroventricular (i.c.v.) administration of NPY regulates the phosphorylation of CREB in hypophysiotropic CRH neurons. NPY [10 micro g in artificial CSF (aCSF)] was administered into the lateral ventricle i.c.v. 30 min before the i.c.v. administration of aCSF or alpha-MSH (10 micro g in aCSF), the latter in a dose previously demonstrated to increase proTRH mRNA and phosphorylate CREB in TRH neurons. By double-labeling immunocytochemistry, only few TRH neurons in the PVN contained phosphoCREB (PCREB) in animals treated only with aCSF (4 +/- 0.2%) or with NPY followed by aCSF (9.7 +/- 2.5), whereas alpha-MSH-infused animals dramatically increased the percentage of TRH neurons containing PCREB (75.3 +/- 6.9%). Pretreatment with NPY before alpha-MSH infusion, however, significantly reduced the percentage of TRH neurons containing PCREB (40.8 +/- 3.5%) compared with alpha-MSH infused animals (P = 0.01). Only 12.2 +/- 0.9% of CRH neurons of the medial parvocellular neurons contained PCREB nuclei in vehicle-treated animals, whereas 30 min following NPY infusion, the number of CRH neurons containing PCREB increased dramatically to 88 +/- 2.9%. Whereas alpha-MSH infusion increased the percentage of CRH neurons that contained PCREB to 56 +/- 2.2% compared with control, animals pretreated with NPY further increased the number of CRH neurons colocalizing with PCREB to 87 +/- 2.5%. These data demonstrate a functional interaction between NPY and alpha-MSH in the regulation of proTRH neurons in the PVN, suggesting that NPY can antagonize alpha-MSH induced activation of the TRH gene by interfering with melanocortin signaling at the postreceptor level, preventing the phosphorylation of CREB. In contrast, NPY infusion increases the phosphorylation of CREB in CRH neurons, indicating that NPY has independent effects on discrete populations of neurons in the PVN, presumably mediated through different signaling mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12488356     DOI: 10.1210/en.2002-220675

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  23 in total

1.  Contribution of TNF-alpha and nuclear factor-kappaB signaling to type 2 iodothyronine deiodinase activation in the mediobasal hypothalamus after lipopolysaccharide administration.

Authors:  Edith Sánchez; Praful S Singru; Gábor Wittmann; Shira S Nouriel; Perry Barrett; Csaba Fekete; Ronald M Lechan
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

2.  Ghrelin activates hypophysiotropic corticotropin-releasing factor neurons independently of the arcuate nucleus.

Authors:  Agustina Cabral; Enrique Portiansky; Edith Sánchez-Jaramillo; Jeffrey M Zigman; Mario Perello
Journal:  Psychoneuroendocrinology       Date:  2016-02-01       Impact factor: 4.905

Review 3.  Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route.

Authors:  Conrad E Johanson; John A Duncan; Edward G Stopa; Andrew Baird
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

Review 4.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

Review 5.  Central regulation of hypothalamic-pituitary-thyroid axis under physiological and pathophysiological conditions.

Authors:  Csaba Fekete; Ronald M Lechan
Journal:  Endocr Rev       Date:  2013-12-13       Impact factor: 19.871

Review 6.  Regulation of appetite to treat obesity.

Authors:  Gilbert W Kim; Jieru E Lin; Michael A Valentino; Francheska Colon-Gonzalez; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

7.  NPY and MC4R signaling regulate thyroid hormone levels during fasting through both central and peripheral pathways.

Authors:  Kristen R Vella; Preeti Ramadoss; Francis S Lam; Jamie C Harris; Felix D Ye; Paul D Same; Nicholas F O'Neill; Eleftheria Maratos-Flier; Anthony N Hollenberg
Journal:  Cell Metab       Date:  2011-11-17       Impact factor: 27.287

8.  Central Sirt1 regulates body weight and energy expenditure along with the POMC-derived peptide α-MSH and the processing enzyme CPE production in diet-induced obese male rats.

Authors:  Nicole E Cyr; Jennifer S Steger; Anika M Toorie; Jonathan Z Yang; Ronald Stuart; Eduardo A Nillni
Journal:  Endocrinology       Date:  2014-04-28       Impact factor: 4.736

9.  Mechanisms by which the orexigen NPY regulates anorexigenic α-MSH and TRH.

Authors:  Nicole E Cyr; Anika M Toorie; Jennifer S Steger; Matthew M Sochat; Samantha Hyner; Mario Perello; Ronald Stuart; Eduardo A Nillni
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-15       Impact factor: 4.310

10.  Transcriptional and pathway analysis in the hypothalamus of newly hatched chicks during fasting and delayed feeding.

Authors:  Stacy E Higgins; Laura E Ellestad; Nares Trakooljul; Fiona McCarthy; Jason Saliba; Larry A Cogburn; Tom E Porter
Journal:  BMC Genomics       Date:  2010-03-09       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.